Show simple item record

dc.contributor.authorArkenau, HT
dc.contributor.authorTabernero, J
dc.contributor.authorShitara, K
dc.contributor.authorDvorkin, M
dc.contributor.authorMansoor, Was
dc.contributor.authorProkharau, A
dc.contributor.authorAlsina, M
dc.contributor.authorGhidini, M
dc.contributor.authorFaustino, C
dc.contributor.authorGorbunova, V
dc.contributor.authorZhavrid, EA
dc.contributor.authorNishikawa, K
dc.contributor.authorHosokawa, A
dc.contributor.authorGanea, D
dc.contributor.authorYalcin, S
dc.contributor.authorBeretta, GD
dc.contributor.authorWinkler, RE
dc.contributor.authorMakris, L
dc.contributor.authorDoi, T
dc.contributor.authorIlson, DH
dc.date.accessioned2019-04-29T09:48:50Z
dc.date.available2019-04-29T09:48:50Z
dc.date.issued2018en
dc.identifier.citationArkenau HT, Tabernero J, Shitara K, Dvorkin M, Mansoor W, Prokharau A, et al. LBA25 TAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer. Annals of Oncology. 2018;29(suppl_8).en
dc.identifier.pmidNo PMIDen
dc.identifier.doi10.1093/annonc/mdy424.027en
dc.identifier.urihttp://hdl.handle.net/10541/621710
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy424.027en
dc.titleTAGS: A phase III, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentSarah Cannon Research Institute SCRI UK, London, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record